News of Note—Flu vaccines, CureVac and more

newspaper
In this week's news of note, InvVax reported positive preclinical results for a universal flu vaccine candidate. (Pixabay)

Here is some other vaccine news of note for the week:

> About 37% of U.S. adults got a flu vaccine last year, according to the CDC. The figure represented about a 6% decline from the prior year. MarketWatch article

> CureVac started a phase 1 study of a mRNA-based rabies vaccine candidate. Release

Sponsored By Digital Pharma Europe

Fierce Pharma Marketing is excited to announce the first virtual Digital Pharma Europe!

This summit will profile best-in-class case studies and senior-level discussions from leaders who are innovating the way we look at the intersection of digital technologies and marketing in Europe.

> ImmusanT kicked off a phase 2 study of its Nexvax2 in patients with celiac disease. Release

> A report found that low vaccine confidence in Europe is contributing to a higher number of disease outbreaks. Reuters article

> Privately held biotech InvVax touted preclinical results for its universal flu vaccine candidate. Release